Modern prophylactic therapies for hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH) have become increasingly prevalent in Hungary, paralleling global trends, and are proving both ...

A CRISPR/Cas9-modified Janus kinase 2 (JAK2) V617F model may be useful to develop new therapies against myeloproliferative neoplasms (MPNs), showed a new study published in the International Journal ...

To assess the effect of NMOSD, MS, and related diseases on employment and income, a team of researchers, led by Jiraporn Jitprapaikulsan, MD, from the Mahidol University in Bangkok, Thailand, ...

When comparing the digital and paper formats of the eMPhasis-10, the responses from patients showed remarkable consistency. In other words, there was a strong association between both digital and ...

Vosoritide, a once-daily injectable therapy, may improve growth outcomes in children with achondroplasia when administered continuously from infancy to final adult height, according to findings of a ...

Researchers from Brazil developed a new clinical score to estimate the probability of neuromyelitis optica spectrum disorder (NMOSD) in patients presenting with optic neuritis. The easily accessible ...

Clinically relevant concentrations of deoxycytidine (dC) and deoxythymidine (dT) are unlikely to cause or be subject to pharmacokinetic drug-drug interactions, according to a new study published in ...

In patients with hepatocellular carcinoma (HCC), serum alpha-fetoprotein (AFP) levels are unreliable as a sole biomarker for disease diagnosis, according to findings from a retrospective study ...

Individuals with homozygous ZZ alpha-1 antitrypsin deficiency (AATD) face a substantial burden of liver disease, according to results of a meta-analysis recently published in Liver International ...

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly identified disease that can manifest as vasculitis (commonly, small-vessel vasculitis), making it a challenge to ...

Two phase 3 clinical trials, MOBILIZE and VITALIZE, are recruiting patients with chronic demyelinating polyneuropathy (CIDP) to evaluate the effectiveness of riliprubart according to an abstract ...

Among the considered first line options for patients with Lennox-Gastaut syndrome (LGS), certain pharmacological and nonpharmacological interventions could be superior in efficacy and hold a safer ...